Abbisko Cayman (HKG:2256) said its investigational drug lavengratinib showed positive preliminary efficacy results in a Phase 2 study for children with achondroplasia, according to an exchange filing.
In the first and lowest-dose cohort, children aged 6 and older who received 0.064 mg/kg once daily for 27 weeks achieved a mean annualized height velocity increase of 2.4 centimeters per year, with a 100% responder rate.